Oct 6, 2022 Web Announcement 2912

## Silver State Scripts Board (SSSB) Made Changes to Preferred Drug List (PDL) Effective October 6, 2022

The Silver State Scripts Board (SSSB) met on Sept 22, 2022, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective Oct 6, 2022.

The complete PDL is posted on the <u>"Preferred Drug List"</u> webpage.

Drug Class/Program	Changes
Toxicology Agents- Antidotes- Opiate Antagonists	Zimhi <sup>®</sup> added as non-preferred
Toxicology Agents- Antidotes- Substance Abuse Agents	naltrexone tab added as preferred Lucemyra® added as non-preferred
Immunomodulators- Atopic Dermatitis	Adbry <sup>®</sup> added as non-preferred Cibinqo <sup>®</sup> added as non-preferred Opzelura <sup>®</sup> added as non-preferred
Antiparkinsonian Agents- Non-Ergot Dopamine Agonists	Kynmobi <sup>®</sup> added as non-preferred
Monoclonal Antibodies for the Treatment of Respiratory Conditions	Tezspire <sup>®</sup> added as non-preferred
Growth Hormone Modifiers	Nutropin AQ <sup>®</sup> moved to preferred Skytrofa <sup>®</sup> added as non-preferred
Incretin Mimetics and Combinations	Mounjaro <sup>®</sup> added as non-preferred

Colony Stimulating Factors	Neupogen <sup>®</sup> added as preferred Nyvepria <sup>®</sup> added as preferred Nivestym <sup>®</sup> added as non-preferred Releuko <sup>®</sup> added as non-preferred Leukine <sup>®</sup> added as non-preferred Zarxio <sup>®</sup> added as non-preferred Granix <sup>®</sup> added as non-preferred Fulphila <sup>®</sup> added as non-preferred Ziextenzo <sup>®</sup> added as non-preferred Udenyca <sup>®</sup> added as non-preferred Neulasta <sup>®</sup> added as non-preferred
Multiple Sclerosis Agents- Oral	dimethyl fumarate moved to preferred Tecfidera® moved to non-preferred
Proton Pump Inhibitors	Protonix <sup>®</sup> suspension added as preferred pantoprazole suspension added as non-preferred
Androgens	AndroGel® gel pump moved to preferred
Neurologic Agents- Anticonvulsants	lacosamide solution added as preferred levetiracetam solution added as preferred Keppra® solution added as non-preferred Vimpat® solution added as non-preferred
Anti-Migraine Agents- CGRP Receptor Antagonists	Ubrelvy® moved to preferred
Anti-Migraine Agents- Triptans	Imitrex <sup>®</sup> nasal spray moved to preferred zolmitriptan nasal spray moved to non-preferred
Antipsychotics- Atypical- Oral/Topical	ziprasidone moved to preferred Geodon® moved to non-preferred
Alzheimer's Agents- Cholinesterase Inhibitors	Adlarity® added as non-preferred
Miscellaneous Analgesics- Mixed Acting Opioid Analgesics	Seglentis® added as non-preferred